Published in J Biol Chem on September 02, 2003
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J (2006) 2.01
Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia (2010) 1.70
CB2 receptors in the brain: role in central immune function. Br J Pharmacol (2007) 1.66
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
Novel cannabinoid receptors. Br J Pharmacol (2007) 1.55
Endocannabinoid signaling in microglial cells. Neuropharmacology (2008) 1.36
Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol (2012) 1.31
Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology (2005) 1.23
Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol (2005) 1.14
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol (2010) 1.10
Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br J Pharmacol (2004) 1.08
N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br J Pharmacol (2010) 1.04
The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels. J Pharmacol Exp Ther (2008) 1.03
Architecture of cannabinoid signaling in mouse retina. J Comp Neurol (2010) 0.99
Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol (2014) 0.98
Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol (2007) 0.96
The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther (2009) 0.95
N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol (2010) 0.91
The GPR55 agonist lysophosphatidylinositol acts as an intracellular messenger and bidirectionally modulates Ca2+ -activated large-conductance K+ channels in endothelial cells. Pflugers Arch (2010) 0.91
Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol (2006) 0.90
Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells. Neuropharmacology (2007) 0.88
N-Arachidonyl glycine does not activate G protein-coupled receptor 18 signaling via canonical pathways. Mol Pharmacol (2012) 0.88
Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol (2013) 0.86
Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors. J Biol Chem (2012) 0.85
"Venopathy" at work: recasting neointimal hyperplasia in a new light. Transl Res (2010) 0.84
Kaempferol stimulates large conductance Ca2+ -activated K+ (BKCa) channels in human umbilical vein endothelial cells via a cAMP/PKA-dependent pathway. Br J Pharmacol (2008) 0.83
Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc Res (2015) 0.82
The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells. Br J Pharmacol (2015) 0.78
Psychotropic and nonpsychotropic cannabis derivatives inhibit human 5-HT(3A) receptors through a receptor desensitization-dependent mechanism. Neuroscience (2011) 0.77
(-)-Trans-Δ(9)-Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users. J Alcohol Drug Depend (2016) 0.75
The Effect of Chronic Activation of the Novel Endocannabinoid Receptor GPR18 on Myocardial Function and Blood Pressure in Conscious Rats. J Cardiovasc Pharmacol (2016) 0.75
Calycosin and Formononetin Induce Endothelium-Dependent Vasodilation by the Activation of Large-Conductance Ca(2+)-Activated K(+) Channels (BKCa). Evid Based Complement Alternat Med (2016) 0.75
Big conductance calcium-activated potassium channel openers control spasticity without sedation. Br J Pharmacol (2017) 0.75
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Concurrent activation of striatal direct and indirect pathways during action initiation. Nature (2013) 4.87
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron (2006) 3.58
Dynamic reorganization of striatal circuits during the acquisition and consolidation of a skill. Nat Neurosci (2009) 3.38
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest (2008) 3.13
Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med (2008) 2.91
Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab (2008) 2.91
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc (2007) 2.84
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci (2003) 2.84
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol (2007) 2.81
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem Biophys Res Commun (2007) 2.51
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci (2003) 2.44
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes (2006) 2.40
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum. Proc Natl Acad Sci U S A (2006) 2.32
Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A (2003) 2.21
Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med (2013) 2.19
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 2.15
CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 2.08
A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A (2006) 2.08
Hyperexcitability and epilepsy associated with disruption of the mouse neuronal-specific K-Cl cotransporter gene. Hippocampus (2002) 2.06
Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology (2012) 2.01
Combined activation of L-type Ca2+ channels and synaptic transmission is sufficient to induce striatal long-term depression. J Neurosci (2007) 2.01
Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 2.00
In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology (2003) 2.00
Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning. J Neurosci (2010) 1.99
Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol (2005) 1.98
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol (2003) 1.95
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94
Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: setting the tone for reward processing. Cell Rep (2012) 1.91
Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology (2008) 1.90
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol (2009) 1.89
Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors. Nat Neurosci (2011) 1.89
Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci (2009) 1.88
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol (2004) 1.88
Activation of NR2A-containing NMDA receptors is not obligatory for NMDA receptor-dependent long-term potentiation. J Neurosci (2005) 1.87
Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther (2006) 1.82
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol (2007) 1.77
Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2005) 1.76
A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood (2007) 1.76
Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci (2004) 1.74
Ethanol induces long-term facilitation of NR2B-NMDA receptor activity in the dorsal striatum: implications for alcohol drinking behavior. J Neurosci (2007) 1.72
Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem (2003) 1.70
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol (2007) 1.68
Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock (2003) 1.64
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab (2007) 1.59
Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology (2007) 1.59
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol (2007) 1.54
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A (2006) 1.52
Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation (2002) 1.52
Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol (2004) 1.51
Investigational A₃ adenosine receptor targeting agents. Expert Opin Investig Drugs (2011) 1.49
The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One (2008) 1.49
A(2B) adenosine receptors in immunity and inflammation. Trends Immunol (2009) 1.48
The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol (2003) 1.48
Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology (2015) 1.48
Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats. Crit Care Med (2003) 1.46
Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock (2002) 1.44
Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol (2006) 1.43
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol (2005) 1.42